These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Ziconotide: can we use it in palliative care? Prommer EE Am J Hosp Palliat Care; 2005; 22(5):369-74. PubMed ID: 16225359 [TBL] [Abstract][Full Text] [Related]
4. Voltage gated calcium channels as targets for analgesics. Bourinet E; Zamponi GW Curr Top Med Chem; 2005; 5(6):539-46. PubMed ID: 16022676 [TBL] [Abstract][Full Text] [Related]
5. Targeting chronic and neuropathic pain: the N-type calcium channel comes of age. Snutch TP NeuroRx; 2005 Oct; 2(4):662-70. PubMed ID: 16489373 [TBL] [Abstract][Full Text] [Related]
6. Analgesic (omega)-conotoxins CVIE and CVIF selectively and voltage-dependently block recombinant and native N-type calcium channels. Berecki G; Motin L; Haythornthwaite A; Vink S; Bansal P; Drinkwater R; Wang CI; Moretta M; Lewis RJ; Alewood PF; Christie MJ; Adams DJ Mol Pharmacol; 2010 Feb; 77(2):139-48. PubMed ID: 19892914 [TBL] [Abstract][Full Text] [Related]
7. Voltage-gated calcium channels in chronic pain: emerging role of alternative splicing. Swayne LA; Bourinet E Pflugers Arch; 2008 Jun; 456(3):459-66. PubMed ID: 18389277 [TBL] [Abstract][Full Text] [Related]
8. Peptide leads new class of chronic pain drugs. Garber K Nat Biotechnol; 2005 Apr; 23(4):399. PubMed ID: 15815650 [No Abstract] [Full Text] [Related]
12. Huwentoxin-XVI, an analgesic, highly reversible mammalian N-type calcium channel antagonist from Chinese tarantula Ornithoctonus huwena. Deng M; Luo X; Xiao Y; Sun Z; Jiang L; Liu Z; Zeng X; Chen H; Tang J; Zeng W; Songping Liang Neuropharmacology; 2014 Apr; 79():657-67. PubMed ID: 24467846 [TBL] [Abstract][Full Text] [Related]
13. An integrated multiassay approach to the discovery of small-molecule N-type voltage-gated calcium channel antagonists. Finley MF; Lubin ML; Neeper MP; Beck E; Liu Y; Flores CM; Qin N Assay Drug Dev Technol; 2010 Dec; 8(6):685-94. PubMed ID: 21050074 [TBL] [Abstract][Full Text] [Related]
14. Targeting voltage-gated calcium channels for the treatment of neuropathic pain: a review of drug development. Pexton T; Moeller-Bertram T; Schilling JM; Wallace MS Expert Opin Investig Drugs; 2011 Sep; 20(9):1277-84. PubMed ID: 21740292 [TBL] [Abstract][Full Text] [Related]
15. Neuropathic pain: role of voltage-dependent calcium channels. Chaplan SR Reg Anesth Pain Med; 2000; 25(3):283-5. PubMed ID: 10834784 [No Abstract] [Full Text] [Related]
16. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Miljanich GP Curr Med Chem; 2004 Dec; 11(23):3029-40. PubMed ID: 15578997 [TBL] [Abstract][Full Text] [Related]
17. Recent progress in the discovery and development of N-type calcium channel modulators for the treatment of pain. Lee MS Prog Med Chem; 2014; 53():147-86. PubMed ID: 24418610 [TBL] [Abstract][Full Text] [Related]
18. Challenging the catechism of therapeutics for chronic neuropathic pain: Targeting CaV2.2 interactions with CRMP2 peptides. Feldman P; Khanna R Neurosci Lett; 2013 Dec; 557 Pt A(0 0):27-36. PubMed ID: 23831344 [TBL] [Abstract][Full Text] [Related]
19. N-type calcium channel blockers: a call for papers. Baumrucker SJ Am J Hosp Palliat Care; 2005; 22(2):91-2. PubMed ID: 15853084 [No Abstract] [Full Text] [Related]
20. Analgesic effects of a substituted N-triazole oxindole (TROX-1), a state-dependent, voltage-gated calcium channel 2 blocker. Abbadie C; McManus OB; Sun SY; Bugianesi RM; Dai G; Haedo RJ; Herrington JB; Kaczorowski GJ; Smith MM; Swensen AM; Warren VA; Williams B; Arneric SP; Eduljee C; Snutch TP; Tringham EW; Jochnowitz N; Liang A; Euan MacIntyre D; McGowan E; Mistry S; White VV; Hoyt SB; London C; Lyons KA; Bunting PB; Volksdorf S; Duffy JL J Pharmacol Exp Ther; 2010 Aug; 334(2):545-55. PubMed ID: 20439438 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]